AK-778-XXMU

AK-778-XXMU is a potent DNA binding inhibitor 2 (ID2) antagonist with a KD of 129 nM. AK-778-XXMU can inhibit cell migration and invasion of glioma cell lines, induce apoptosis, and exhibits significant cancer-suppressing potency. AK-778-XXMU inhibits the ID2-KDR signaling axis, thereby down-regulating the downstream angiogenic factors (VEGFA) and invasion-related proteins (MMP2/9), and up-regulating the tumor suppressor factor (PTEN) . AK-778-XXMU can be used for the study of glioma[1].

Product Specifications

CAS Number

[1227045-76-2]

UNSPSC

12352005

Target

Apoptosis; MMP; PTEN; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ak-778-xxmu.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=CC=N1)CC2(C(N(C3=C2C=CC=C3)CC4=CC=CC(Cl)=C4)=O)O

Molecular Formula

C22H17ClN2O3

Molecular Weight

392.83

References & Citations

[1]Zhong G, et al. Discovery of novel ID2 antagonists from pharmacophore-based virtual screening as potential therapeutics for glioma. Bioorg Med Chem. 2021;49:116427.